Originally published February 16 2006
GSK diabetes drug Avandia reported to cause eye problems
by Mike Adams, the Health Ranger, NaturalNews Editor
The FDA alerted Medwatch about numerous reports that Avandia, a diabetes drug manufactured by GlaxoSmithKline, has been causing a swelling at the back of the eye known as macular edema.
GlaxoSmithKline Plc's Avandia diabetes drug has been linked to swelling in the back of the eye, which can reduce vision, U.S. regulators said.
The Food and Drug Administration sent an e-mail notice today about the complication, known as macular edema, to about 54,000 subscribers of MedWatch, the agency's alert system.
The FDA also forwarded a letter that Glaxo sent last month to doctors, saying the company received reports of both new and worsening cases of swelling in people taking Avandia.
People with diabetes already are at higher risk of eye complications because of the disorder, which results in the blood vessels at the back of the eye, or retina, becoming leaky and swelling.
European regulators last month also said they are reviewing macular edema reports in people using Avandia and Takeda Pharmaceutical Co.'s similar Actos drug.
``Even though the reported incidence is very rare, we felt a need to alert doctors,'' said Bernadette King, a Glaxo spokeswoman, in a telephone interview.
She said the cause of the swelling is not clear.
The swelling can cause blurred vision and changes in how color and darkness are perceived, the Glaxo letter said.
There is less than one report of macular edema for every 10,000 patients estimated to have taken Avandia, King said.
Avandia and Actos are used by people with Type 2 diabetes, the most common form, in which the body fails to produce enough insulin to keep blood sugar well controlled.
London-based Glaxo is the world's second-largest drugmaker, behind Pfizer Inc. American depositary receipts of Glaxo were unchanged at $51.95 as of 3:02 p.m. in New York Stock Exchange composite trading.
Calls to Takeda's U.S. offices in Lincolnshire, Illinois, were not immediately returned.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml